PE20011272A1 - COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELIN - Google Patents

COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELIN

Info

Publication number
PE20011272A1
PE20011272A1 PE2001000482A PE2001000482A PE20011272A1 PE 20011272 A1 PE20011272 A1 PE 20011272A1 PE 2001000482 A PE2001000482 A PE 2001000482A PE 2001000482 A PE2001000482 A PE 2001000482A PE 20011272 A1 PE20011272 A1 PE 20011272A1
Authority
PE
Peru
Prior art keywords
combination
effect
intense
montirelin
active substances
Prior art date
Application number
PE2001000482A
Other languages
Spanish (es)
Inventor
Boris Chizh
Thomas Christoph
Wolfgang Strassburger
Achim Schuttler
Babette-Yvonne Kogel
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20011272A1 publication Critical patent/PE20011272A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE: a) MONTIRELINA DE FORMULA I Y b) UN COMPUESTO DE EFECTO OPIODE DE EFECTO DEBIL TAL COMO CODEINA, DEXTROPROPOXIFEN, DIHIDROCODEINA, DIFENOXILATO, ETILMORFINA, MEPTAZINOL, TRAMADOL, PETIDINA, ENTRE OTROS; OPIOIDE DE EFECTO INTENSO TAL COMO BUTORFANOL, DEXTROMORAMIDA, DIACELTILMORFINA, ENTRE OTROS; OPIODE DE EFECTO MUY INTENSO TAL COMO TAL COMO ALFENTANIL, BUPRENORFINA, ETORFINA, FENTANIL, ENTRE OTROS. LA RELACION PONDERAL ENTRE a Y b SE ENCUENTRA EN EL INTERVALO DE 1:10 HASTA 1: 2000 DE PREFERENCIA DE 1: 50. LA FORMULACION SE CARACTERIZA PORQUE AL MENOS UNO DE LOS COMPONENTES DE a) O b) SE ENCUENTRA EN FORMA RETARDADA PRODUCIDA POR UN REVESTIMIENTO RETARDANTE, FIJACION EN UNA RESINA INTERCAMBIADORA IONICA, INCRUSTACION EN UNA MATRIZ RETARDANTE O COMBINACION DE LOS MISMOS. LA COMBINACION ES UTIL PARA EL TRATAMIENTO DE DOLORES INTENSOS, DOLORES CRONICOS, AGUDOSIT REFERS TO A COMBINATION THAT INCLUDES: a) MONTIRELINE OF FORMULA I AND b) A COMPOUND WITH OPIODE EFFECT WITH WEAK EFFECT SUCH AS CODEINE, DEXTROPROPOXIFEN, DIHYDROCODEINE, DIPHENOXYLATE, ETHYLMORPHOLE, MEPTAZYLATE, PETIRAMORPHOLE, TRUTHYLINTHINE; OPIOID WITH INTENSE EFFECT SUCH AS BUTORPHANOL, DEXTROMORAMIDE, DIACELTILMORPHINE, AMONG OTHERS; OPIOD WITH A VERY INTENSE EFFECT SUCH AS ALFENTANIL, BUPRENORPHINE, ETORPHINE, FENTANIL, AMONG OTHERS. THE PONDERAL RATIO BETWEEN a AND b IS IN THE INTERVAL OF 1:10 TO 1: 2000, PREFERENCE OF 1: 50. THE FORMULATION IS CHARACTERIZED BECAUSE AT LEAST ONE OF THE COMPONENTS OF a) OR b) IS IN A DELAYED FORM PRODUCED BY A RETARDING COATING, FIXING IN AN IONIC EXCHANGER RESIN, INCRUSTATION IN A RETARDING MATRIX OR COMBINATION OF THE SAME. THE COMBINATION IS USEFUL FOR THE TREATMENT OF INTENSE PAIN, CHRONIC PAIN, ACUTE

PE2001000482A 2000-05-26 2001-05-25 COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELIN PE20011272A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10025947A DE10025947A1 (en) 2000-05-26 2000-05-26 Active ingredient combination containing montirelin and a compound with opioid activity

Publications (1)

Publication Number Publication Date
PE20011272A1 true PE20011272A1 (en) 2002-01-26

Family

ID=7643551

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000482A PE20011272A1 (en) 2000-05-26 2001-05-25 COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELIN

Country Status (5)

Country Link
AR (1) AR029096A1 (en)
AU (1) AU2001274020A1 (en)
DE (1) DE10025947A1 (en)
PE (1) PE20011272A1 (en)
WO (1) WO2001091733A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2011106416A2 (en) * 2010-02-24 2011-09-01 Cima Labs Inc. Abuse-resistant formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant

Also Published As

Publication number Publication date
WO2001091733A3 (en) 2002-04-04
WO2001091733A2 (en) 2001-12-06
AR029096A1 (en) 2003-06-04
AU2001274020A1 (en) 2001-12-11
DE10025947A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
ES2164785T3 (en) ORAL COMPOSITIONS CONTAINING STABILIZED STANNY COMPOUNDS.
BR0211390A (en) Treatment of nail infections with at
HK1090293A1 (en) Topical stabilized prostaglandin e compound dosage forms
AR043634A1 (en) COMPOSITIONS CONTAINING SACARALOSA
BR9808181A (en) Use of a wood preservative and wrap for supplemental wood protection
BR9913433A (en) Stabilized disinfectant system composed of two parts and related compositions and methods
RU2009114849A (en) SELF-CONSERVING WATER PHARMACEUTICAL COMPOSITIONS
UY24354A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTINE
AR046933A1 (en) EFFECTIVENESS OF IMPROVED HUMECTATION THROUGH THE USE OF HYDROXIALQUILUREA
TR200201874T2 (en) New compounds and compositions as protease inhibitors.
MXPA01012882A (en) Compositions and methods comprising morphine gluconate.
ES2133324T3 (en) SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
TW200501947A (en) Stabilized pharmaceutical composition comprising an amorphous active substance
BRPI0408221A (en) dispensing devices
HUP0101692A2 (en) Plant growth regulator composition containing a mepiquat derivative, its use and processes for the preparation of the active ingredient
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
PE123899A1 (en) FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ALPHA-ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC
EA200800788A1 (en) ФУНГИЦИДНЫЕ MIXES OF TRIAZOLOV BASES
PE20011272A1 (en) COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELIN
RU2007119641A (en) COMPOSITION INCLUDING ACETAMINOPHEN, CAFFEINE AND OPTIONAL ASPIRINE IN A MIXTURE WITH AN ALKALINE AGENT FOR INCREASING ABSORPTION
AR039907A1 (en) COSMETIC COMPOSITIONS WITH AMMONIUM MALONATES
MXPA02010828A (en) Pharmaceutical composition in capsules comprising a non-steroidal anti-inflammatory and an opiate analgesic for handling pain.
ATE412404T1 (en) STABLE ORAL PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE AND SALT THEREOF
TW200603742A (en) Dry composition for oral uptake, and in-use-preparing gel composition for oral uptake
PE20020041A1 (en) PHARMACEUTICAL COMBINATION INCLUDING A COMPOUND WITH OPIOID EFFECT AND A PEPTIDIC COMPOUND

Legal Events

Date Code Title Description
FA Abandonment or withdrawal